Table 1.
Description of Study and Baseline Characteristics for Included Studies
| Drug | Author Year | Study Duration (years) |
Country/Region | Number of Centres |
Age (yrs) Mean(SD) |
Years Menopause Inclusion Criteria |
Years Since Menopause Mean (SD) |
BMD Hip g/cm2 Mean (SD) |
Prior Vertebral Fracture % |
|---|---|---|---|---|---|---|---|---|---|
| Alendronate | Ascott Evans 2003 | 1 | International | 18 | 67.3 (6.6) | 3 | 11.5 (7.3) | nr | 0 |
| Alendronate | Black 1996 | 3 | North America | 11 | 71.0 (5.6) | 2 | NR (NR) | 0.57 (0.07) | 100 |
| Alendronate | Cummings 1998 | 4 | North America | 11 | 67.6 (6.1) | 2 | NR (NR) | 0.84 (0.13) | 0 |
| Alendronate | Greenspan 1998 | 2.5 | North America | 1 | 70.0 (4.6) | NR | NR (NR) | 0.57 (0.11) | NR |
| Alendronate | Liberman 1995 | 3 | International | NR | 64.0 (7.0) | 5 | 16.5 (NR) | 0.71 (NR) | 21 |
| Alendronate | Pols 1999 | 1 | International | 153 | 62.8 (7.4) | 3 | 15.9 (1.5) | 0.72 (0.08) | NR |
| Denosumab | Cummings 2009 | 4 | North America | 11 | 67.7 (6.6) | 2 | NR (NR) | 0.84 (0.13) | 0 |
| Etidronate | Lyritis 1997 | 4 | Europe | 1 | 72.0 (0.4) | NR | 25.8 (1.7) | 0.57 (NR) | 100 |
| Etidronate | Meunier 1997 | 4 | Europe | 1 | 52.7 (4.0) | 0.5 | 2.4 91.8) | 0.90 (NR) | NR |
| Etidronate | Montesorri 1997 | 3 | Europe | 2 | 62.5 (6.2) | 1 | 14.9 (6.1) | 0.67 (NR) | 29 |
| Etidronate | Pacifici 1988 | 2 | U.S.A | 1 | 61.0 (7.8) | NR | 13.8 (9.5) | 0.79 (0.26) | 100 |
| Etidronate | Pouilles 1997 | 2 | Europe | 7 | 53.8 (3.1) | 0.5 | 2.6 (1.4) | 0.96 (NR) | NR |
| Etidronate | Storm 1990 | 3 | Europe | 1 | 68.3 (7.3) | NR | 21.6 (10.2) | 0.25 (0.07) | 100 |
| Etidronate | Watts 1990 | 2 | U.S.A | 7 | 65.1 (13.0) | 1 | 17.9 (16.5) | 0.86 (NR) | 100 |
| Etidronate | Wimalawansa 1998 | 4 | NR | NR | 64.9 (7.8) | NR | 15.1 (6.8) | 0.83 (NR) | 100 |
| Ibandronate | Chesnut 2004 | 3 | Europe, U.S.A | 73 | 69.0 (11.0) | 5 | 21 (20.8) | 0.78 (NR) | 93 |
| Ibandronate | Ravn 2002 | 1 | Europe | 1 | 64.5 (5.9) | 10 | NR (NR) | 0.87 (0.13) | 28 |
| Ibandronate | Adami 2004 | 1 | Europe | NR | 65.9 (4.5) | 5 | 17.9 (4.0) | 0.77 (0.09) | 45 |
| Ibandronate | Recker 2004 | 3 | Europe | NR | 67.0 (5.1) | 5 | NR (NR) | 0.80 (0.11) | 54 |
| Raloxifene | Ettinger 1999 | 3 | International | 180 | 66.1 (6.9) | 2 | 18.6 (7.9) | 0.58 (NR) | 38 |
| Risedronate | Fogelman 2000 | 2 | Europe | 13 | 64.7 (7.2) | 1 | 17.7 (9.4) | 0.74 (0.08) | 30 |
| Risedronate | Harris 1999 | 3 | North America | 110 | 69.0 (7.3) | 5 | 24.0 (9.9) | 0.83 (0.16) | 81 |
| Risedronate | Hooper 2005 | 2 | Australia | 11 | 52.6 (3.3) | 0.5 | 3.9 (5.6) | 1.08 (0.12) | 18.3 |
| Risedronate | McClung 2001 | 3 | International | 183 | 78.0 (9.7) | NR | 31.8 (19.3) | NR (NR) | 42 |
| Risedronate | Mortenson 1998 | 2 | International | 2 | 51.2 (3.8) | 0.5 | 2.7 91.7) | 0.94 (0.11) | NR |
| Risedronate | Reginster 2000 | 3 | Europe, Australia | 80 | 71.0 (7.0) | 5 | 24.4 (8.5) | 0.79 (0.15) | 100 |
| Strontium | Meunier 2004 | 3 | Europe, International | 72 | 69.3 (7.3) | 5 | 43.7 (8.7) | 0.68 (0.11) | 100 |
| Strontium | Reginster 2008 | 3.5 | International | 75 | 76.7 (5.0) | 0 | 28.4 (7.4) | 0.55 (NR) | 33.5 |
| Teriparatide | Neer 2001 | 2 | International | 99 | 69.0 (7.0) | 5 | 21.0 (8.0) | 0.82 (0.17) | 100 |
| Zoledronate | Black 2007 | 3 | U.S.A, Europe | 60 | 73 (5.4) | 0 | NR (NR) | 0.65 (0.91) | 36.7 |
NR: Not reported. BMD: Bone Mineral Density. SD: Standard deviation. U.S.A: United States of America